Black Diamond Therapeutics, Inc. Share Price

Black Diamond Therapeutics, Inc. Share Price

NASDAQ: BDTX | Micro Cap
$1.85
+$0.03 (1.37%) Last updated on 29 Oct, 2026 | 19:54 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Black Diamond Therapeutics, Inc. Stock Performance

Open
$1.83
Prev. Close
$1.82
Circuit Range
N/A
Day Range
$1.83 - $1.88
Year Range
$1.60 - $4.94
Volume
9,458
Average Traded
$1.86

Black Diamond Therapeutics, Inc. Share Price Today

As of 29 October 2026, Black Diamond Therapeutics, Inc.'s share price is $1.85. The stock opened at $1.83, compared to its previous close of $1.82. During today's trading session, Black Diamond Therapeutics, Inc.'s share price traded between $1.83 and $1.88, with an average price of $1.85. Over the past 52 weeks, the stock has recorded a high of $4.94 and a low of $1.60. In terms of performance, Black Diamond Therapeutics, Inc.'s share price has declined by 30.45% over the last six months and is down 52.44% on a year-on-year basis.

Black Diamond Therapeutics, Inc. Share Price Chart

Line chart of the Black Diamond Therapeutics, Inc. price trend over the selected period. The price rose overall, ranging from 1.82 to 1.88, ending at 1.85.
$1.83$1.88
L
Show Current Price
H

Black Diamond Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$105.21M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.74
Revenue (TTM)
$70.00B
Return On Equity (TTM)
-44.29%
Profit Margin
31.96%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-16.59%

Black Diamond Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$8.50-$15.12-$9.04-$9.91
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-77.88%40.21%-9.62%

Black Diamond Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$70.00
Net Profit-$91.17-$82.44-$69.68$22.37
Net Profit MarginN/AN/AN/A31.96%
Income ChangeN/A9.58%15.48%132.10%

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Black Diamond Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$1.87
$1.85
-1.60%
Sep 2026
$2.09
$1.88
-17.18%
Aug 2026
$1.68
$2.27
+34.72%
Jul 2026
$1.85
$1.69
-8.67%
Jun 2026
$2.21
$1.84
-17.63%
May 2026
$2.63
$2.24
-15.79%
Apr 2026
$2.24
$2.66
+24.88%
Mar 2026
$2.34
$2.13
-13.59%
Feb 2026
$2.47
$2.46
-0.60%
Jan 2026
$2.46
$2.48
+1.64%
Dec 2025
$3.76
$2.44
-36.13%
Nov 2025
$3.95
$3.82
-1.80%

BDTX Share Price FAQs